ASX News

Leader in prostate cancer imaging Prof. Frederik L. Giesel joins Scientific Advisory Board

Melbourne (Australia) – 9 March 2020. Telix Pharmaceuticals Limited announces that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board.

Telix Pharmaceuticals Limited is pleased to announce that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board (SAB).

As a member of Telix’s Scientific Advisory Board, Prof. Giesel will advise Telix in relation to its R&D and clinical development activities spanning the Company’s prostate cancer, kidney cancer and glioblastoma (brain cancer) programs.

To read the full media release please click here.

More Articles

ASX News

Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging

Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...

ASX News

Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging

Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...

ASX News

FDA Grants Orphan Drug Designation for TLX102

Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...

ASX News

Half Year Shareholder Update

Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update

ASX News

First patient dosed in renal cancer imaging study in Japan

Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...

ASX News

Telix H1 2020 Results and Company Update Conference Call

Melbourne (Australia) – 11th August 2020. Telix will hold an investor conference call to present the Company’s H1 2020 financial...

ASX News

Drug Master File for Glioblastoma Therapy Product Filed with FDA

Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...

ASX News

Activities Report and Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th...

ASX News

Telix Pharmaceuticals Receives $11.4M R&D Tax Refund

Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to...

ASX News

Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers

Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical

ASX News

Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product

Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...

Corporate Spotlight

Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020

25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)